A Phase 2/3, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of GX-19N, A DNA Vaccine, in Healthy Individuals Who Have Received One of the COVID-19 Vaccines
Latest Information Update: 06 Feb 2023
At a glance
- Drugs GX 19N (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Genexine
- 04 Apr 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 07 Oct 2021 New trial record